Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

Grail Inc.’s multi-cancer blood test, Galleri, failed to hit its primary goal in a large-scale National Health Service trial, ...

Medically reviewed by Qin Rao, MD Key Takeaways Regular colon cancer screenings can help find and treat the disease ...

Colorectal cancer (CRC) is a major public health issue, with over 43,000 new cases and nearly 17,700 deaths annually in France. The overall survival rate is currently 63%. It is much higher for early ...

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

When Erica Barnell was an MD/PhD student at Washington University in St. Louis, she met a woman who had stage four colorectal cancer (CRC). The woman was only 52 years old—more than a decade younger ...

Is the Galleri multi-cancer blood test worth it? A doctor explains real-world performance data and explains why no major ...

A new CRISPR-powered light sensor can detect the faintest whispers of cancer in a single drop of blood.

Ebihara Takashi has been the chief operating officer of GeneFrontier (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. He earned a ...

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...